TP-317 for Treatment of IBD
TP-317 is a unique derivative of a newly discovered class of bioactive lipids known as specialized pro-resolving mediators (SPMs).
SPMs are a potent class of endogenous metabolites of Omega-3 and Omega-6 fatty acids that have been shown pre-clinically to control gastrointestinal inflammation and gut mucosal immune responses at very small doses. These data suggest multiple mechanisms of action including inhibition of pro-inflammatory signals, reduced penetration of bacteria into the intestinal wall, and promotion of tissue repair and healing. TP-317 has the potential to be a non-immunosuppressive alternative or complement to biologics for treatment of IBD. TP-317 is undergoing pre-clinical studies.